A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716

Slides:

Advertisements

Similar presentations

Supplemental Figures Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cristina Cadenas 1*, Leonie van de Sandt.

Advertisements

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.

Date of download: 6/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of BRCA1 and BRCA2 Mutations With Survival,

Vignesh Ramachandran SMART Summer Research Program

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

C Supplemental Figure S2.. C Supplemental Figure S2.

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

Luminal A normal-like Figure S12: KNN graph analysis showed that the cancer data consists of a series of connected, bifurcating clusters. luminal B normal.

Gene expression arrays in cancer research: methods and applications

Hallett, et al., - Supplementary Figure 1

Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors Anita Muthukaruppan, Annette Lasham,

Figure S1. DCYTB expression is higher in ER+ than ER- patients

(A) Schematic diagrams demonstrating the HER2 mutational heterogeneity among and between cases of invasive breast cancer (n=963), bladder urothelial cancer.

KDM1B Expression in Richardson Breast 2

M. Fu, G. Huang, Z. Zhang, J. Liu, Z. Zhang, Z. Huang, B. Yu, F. Meng

Genes with Bimodal Expression Are Robust Diagnostic Targets that Define Distinct Subtypes of Epithelial Ovarian Cancer with Different Overall Survival

a b SUM149PT Motility Invasion C V C V

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

سرطان الثدي Breast Cancer

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

Volume 68, Issue 4, Pages (October 2015)

Volume 145, Issue 1, Pages (April 2017)

Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer Peng Kuang, Zuhua.

HIC1 Expression Distinguishes Intestinal Carcinomas Sensitive to Chemotherapy Lucie Janeckova, Michal Kolar, Jiri Svec, Lucie Lanikova, Vendula Pospichalova,

Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA.

Volume 8, Issue 5, Pages (May 2017)

Volume 2, Issue 4, Pages (April 2008)

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis Diana Ramirez-Ardila, A. Mieke Timmermans,

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar

(A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza) for 4 d. (A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza)

PPARγ signaling correlates with LATS2 in human and mouse tumors and promotes cell death in a LATS2-dependent manner. PPARγ signaling correlates with LATS2.

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities Martin Lauss, Jeremie Nsengimana, Johan Staaf, Julia Newton-Bishop, Göran.

Volume 32, Issue 1, Pages e8 (July 2017)

Volume 31, Issue 2, Pages (February 2017)

Volume 4, Issue 3, Pages (August 2013)

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

Volume 17, Issue 5, Pages (October 2016)

Gergana Metodieva, Samson Adoki, Berthold Lausen, Metodi V. Metodiev

Volume 17, Issue 8, Pages (November 2016)

Volume 10, Issue 6, Pages (December 2006)

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.

Volume 23, Issue 5, Pages (May 2016)

Derivation and application of cancer‐specific epithelial‐mesenchymal transition (EMT) signature A six‐step scheme illustrating the generation of a cancer‐specific.

Volume 15, Issue 12, Pages (June 2016)

ADAM8 is overexpressed in human breast cancer AADAM8 mRNA expression in samples from breast tumor and normal breast tissue was analyzed using the Oncomine.

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB.

Expression of RUNX2 correlates with ER/PR/HER2-negative human breast cancer. Expression of RUNX2 correlates with ER/PR/HER2-negative human breast cancer.

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

(A) Relative expression levels of the top most down-regulated genes in LATS2L breast tumors (TCGA-BRCA dataset, see Fig 1) in the panel of breast cancer.

Neal S Goldstein, MD The Annals of Thoracic Surgery

MW (kDa) 2 µg 0.5 µg Supplementary Figure S1. SDS-PAGE under reducing condition analysis (Coomassie brilliant blue staining) of.

Supplementary Figure S1

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

Ki-67 expression is determined by the cell-cycle stage.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Reduced number and impaired effector functions of TILs in tumors with PTEN deletion or loss-of-function mutations in PTEN. Cutaneous melanoma patients.

Fig. 5 Proportions of EpCAM+ systemic tumor cells correlate with the clinical outcome of patients with MBC. Proportions of EpCAM+ systemic tumor cells.

Volume 26, Issue 11, Pages e6 (March 2019)

Volume 28, Issue 3, Pages e7 (July 2019)

G34 H3K36me3 upregulates MYCN which is selectively targetable by kinases that destabilize the protein. G34 H3K36me3 upregulates MYCN which is selectively.

The ovarian cancer cell lines modestly recapitulate the spectrum of mutations found in primary ovarian tumors. The ovarian cancer cell lines modestly recapitulate.

Subtype classification of breast functional screening results.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Fig. 1. FAM83H over-expression is associated with poor prognosis of CC

Presentation transcript:

A B C ErbB3 protein levels ERBB3 mRNA levels P = 0.009 P = 0.716 RPPA score ESR1 P-S118 RPPA score ESR1 P-S118 ErbB3 high ErbB3 low ERBB3 high ERBB3 low Supp Fig. S1. Oncoprint analysis of TCGA-curated Luminal A/B breast cancers demonstrating ErbB3 protein upregulation (based on RPPA score) in 13% of all Luminal A/B tumors (N = 324). Subtype row indicates Luminal A (Green) and Luminal B (Blue). TCGA curated luminal A/B breast cancers were bifurcated into tumors with high ErbB3 protein expression (based on RPPA score) and assessed for ESR1 P-S118 RPPA scores. TCGA curated luminal A/B breast cancers were bifurcated into tumors with high ERBB3 mRNA expression and assessed for ESR1 P-S118 RPPA scores.

ErbB3 (RPPA score) NEDD4 high NEDD4 low Supp Fig. S2. TCGA curated luminal A/B breast cancers were bifurcated into tumors with high NEDD4 mRNA expression and assessed for ErbB3 RPPA scores.

Nrdp1 (201961_s_at) NEDD4 (213012_at) months months Supp Fig. S3. Transcript levels of Nrdp1 and NEDD4 were assessed in tamoxifen-treated breast cancer expression microarray datasets and used to generate a Kaplan-Meier survival curve using KmPlot.com. Analysis included all tumors treated with or without chemotherapy, and excluded all samples not treated with tamoxifen. The probes used for analysis are indicated at top of panel.

P-ESR1 S118 (RPPA score) LRIG1 mRNA levels Nrdp1 mRNA levels NEDD4 mRNA levels P = 0.003 P-ESR1 S118 (RPPA score) LRIG1 high LRIG1 low Nrdp1 high Nrdp1 low NEDD4 high NEDD4 low P = 0.617 P = 0.490 Supp Fig. S4. Using TCGA-curated luminal breast cancer datasets, the RPPA protein score for ESR1 (ER) P-S118 was plotted for those tumors with high LRIG1, NRDP1, and NEDD4 mRNA expression as compared to the remaining luminal tumors. Midlines represent average, whiskers indicate S.D. Analysis was performed on cBioPortal.org.